Oxford-AstraZenecaBritain made a new decision regarding the vaccine while the debates about it continued. Pharmaceuticals and Healthcare Products Regulatory Authority (MHRAIn the statement, it was stated that the Oxford-AstraZeneca vaccine still has great benefits in preventing serious diseases. In the statement, which was announced that 79 blood clotting cases were reported until 31 March and 19 of these people died, it was emphasized that it was not determined what caused the blood clotting. It was…"‘Oxford-AstraZeneca’ will not be made for under 30s in England"
In the UK, it was stated that 30 of 18.1 million people with the Oxford-AstraZeneca new type of coronavirus (Kovid-19) vaccine developed blood clots. In a statement made by the UK Medicines and Health Products Regulatory Authority (MHRA), it was noted that 7 of these 30 people died as of March 24. It was stated that there is currently no evidence to suggest a link between blood clots and the Oxford-AstraZeneca vaccine, and the benefits…"7 people died of Oxford-AstraZeneca vaccine in the UK from blood clotting"
The UK Public Health Agency published the first findings on the effect of Pfizer-BioNTech and Oxford-AstraZeneca vaccines in reducing Covid-19 infections. Accordingly, 4 weeks after the vaccine, it was determined that a single dose of the Pfizer-BioNTech vaccine was 57-61 percent effective in protection against Covid-19, and the Oxford-AstraZeneca vaccine was 60-73 percent effective. It was determined that a single dose of both vaccines was more than 80 percent effective in preventing hospitalizations in those…"Single dose of Pfizer-BioNTech and Oxford-AstraZeneca is more than 80 percent effective in preventing hospitalizations – Health News"